Effexor Related Published Studies
Well-designed clinical trials related to Effexor (Venlafaxine)
Effects of venlafaxine extended release on resilience in posttraumatic stress disorder: an item analysis of the Connor-Davidson Resilience Scale. [2008.09]
Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. [2008.09]
Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. [2008.07.17]
The effects of venlafaxine on cognitive functions and quantitative EEG in healthy volunteers. [2008.07]
Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. [2008.07]
The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. [2008.07]
Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. [2008.07]
A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. [2008.06]
Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: A randomized, parallel group, open-label trial. [2008.05.15]
Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. [2008.05]
Effect of the Antidepressant Venlafaxine in Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Trial. [2008.04.17]
The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. [2008.04.15]
Venlafaxine for Acute Heroin Detoxification: A Double-Blind, Randomized, Control Trial. [2008.04]
Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression. [2008.04]
The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder. [2008.04]
An investigation of the effect of immediate and extended release venlafaxine on nocturnal melatonin and cortisol release in healthy adult volunteers. [2008.03]
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. [2008.02.27]
Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine. [2008.02]
Safety and efficacy of venlafaxine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomised study. [2008.02]
A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. [2008.01]
Venlafaxine versus Mirtazapine in the Treatment of Undifferentiated Somatoform Disorder : A 12-Week Prospective, Open-Label, Randomized, Parallel-Group Trial. [2008]
Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. [2008]
Venlafaxine versus nortriptyline in the treatment of elderly depressed inpatients: a randomised, double-blind, controlled trial. [2007.12]
Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. [2007.11.29]
A Randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. [2007.11.15]
A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. [2007.10]
Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER. [2007.09]
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. [2007.08]
Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. [2007.07]
A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. [2007.06.23]
A Randomized Controlled Trial of Venlafaxine ER Versus Placebo in Pediatric Social Anxiety Disorder. [2007.06.04]
A Placebo-Controlled Double-Blind Randomized Study of Venlafaxine in the Treatment of Depression in Dementia. [2007.05.10]
Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. [2007.05]
Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. [2007.05]
Differential physiological effects of a low dose and high doses of venlafaxine in major depression. [2007.02]
Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. [2007.02]
A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia. [2007]
Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. [2007]
A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. [2006.11]
Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. [2006.10]
A comparison of the efficacy and tolerability of reboxetine and sertraline versus venlafaxine in major depressive disorder: a randomized, open-labeled clinical trial. [2006.09.30]
Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. [2006.09]
Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study. [2006.07]
Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder. [2006.06]
Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. [2006.06]
Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. [2006.06]
Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. [2006.05]
[Effectiveness of venlafaxine extended release and conventional antidepressants in elderly patients with depressive disorder] [2006.05]
A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. [2006.04]
Effects of paroxetine and venlafaxine on immune parameters in patients with obsessive compulsive disorder. [2006.04]
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. [2006.03.23]
Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. [2006.03.20]
Efficacy of hormone therapy with and without methyltestosterone augmentation of venlafaxine in the treatment of postmenopausal depression: a double-blind controlled pilot study. [2006.03]
Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. [2006.02]
Does rTMS Hasten the Response to Escitalopram, Sertraline, or Venlafaxine in Patients With Major Depressive Disorder? A Double-Blind, Randomized, Sham-Controlled Trial. [2005.12]
Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. [2005.10]
Effects of paroxetine and venlafaxine XR on heart rate variability in depression. [2005.10]
Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. [2005.09.16]
The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. [2005.08]
Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. [2005.07]
Do venlafaxine XR and paroxetine equally influence negative and positive affect? [2005.04]
Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo. [2005.04]
Efficacy screening trials of paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine in cocaine dependence. [2005.03]
The efficacy and safety of venlafaxine in the prophylaxis of migraine. [2005.02]
A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. [2005.02]
Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. [2005.02]
Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. [2005.01]
Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification. [2005.01]
Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. [2005.01]
Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. [2005]
Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. [2004.12]
Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. [2004.12]
Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study. [2004.11]
A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. [2004.10]
A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. [2004.09]
Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. [2004.08]
Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. [2004.08]
Social adjustment in generalised anxiety disorder: a long-term placebo-controlled study of venlafaxine extended release. [2004.08]
A double-blind, randomized, 26-week study comparing the cognitive and psychomotor effects and efficacy of 75 mg (37.5 mg b.i.d.) venlafaxine and 75 mg (25 mg mane, 50 mg nocte) dothiepin in elderly patients with moderate major depression being treated in general practice. [2004.06]
Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. [2004.05]
Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. [2004.03]
Venlafaxine versus placebo in the preventive treatment of recurrent major depression. [2004.03]
Evaluation of efficacy of the perioperative administration of venlafaxine XR in the prevention of postmastectomy pain syndrome. [2004.02]
Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. [2004.02]
A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. [2004.01]
A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. [2004]
Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder. [2004]
A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. [2003.12]
A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. [2003.10]
Efficacy and safety of venlafaxine ER vs. amitriptyline ER in patients with major depression of moderate severity. [2003.09]
Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. [2003.08]
A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder. [2003.06]
Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. [2003.05]
Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. [2003.04.22]
Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. [2003.03]
Single-blind comparison of venlafaxine and nortriptyline in elderly major depression. [2003.02]
Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: results of a survival analysis. [2002.12]
Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. [2002.11]
Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine. [2002.11]
Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. [2002.06]
A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. [2002.06]
|
